Posted by Michael Wonder on 05 Jul 2023
ICER to assess treatment for schizophrenia
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open to public comment until 26 July 2023.
The ICER announced today that it will assess the comparative clinical effectiveness and value of xanomeline tartrate with trospium chloride (KarXT, Karuna Therapeutics) for the treatment of schizophrenia.
